Significance: Angiogenesis inhibition with humanized antibodies targeting vascular
endothelial growth factor (VEGF) or orally active small tyrosine kinase inhibitors targeting …

Inhibition of angiogenesis with humanized monoclonal antibodies to vascular endothelial
growth factor (VEGF) or with tyrosine kinase inhibitors targeting VEGF receptors has become …

Angiogenesis inhibition by blocking vascular endothelial growth factor (VEGF)-mediated
signalling with monoclonal antibodies or tyrosine kinase inhibitors has become an …

Angiogenesis inhibition with sunitinib, a multitarget tyrosine kinase inhibitor of the vascular
endothelial growth factor receptor, is associated with hypertension and cardiac toxicity, of …

Angiogenesis inhibition is an established treatment for several tumor types. Unfortunately,
this therapy is associated with adverse effects, including hypertension and renal toxicity …

Angiogenesis inhibition with agents targeting tyrosine kinases of vascular endothelial
growth factor receptors is an established anticancer treatment, but is, unfortunately …

Context: Anticancer treatment with the tyrosine kinase inhibitor sunitinib causes thyroid
dysfunction. Objective: Our objective was to investigate the time course and underlying …

Common adverse effects of angiogenesis inhibition are hypertension and renal injury. To
determine the most optimal way to prevent these adverse effects and to explore their …

Hypertension and renal injury are off-target effects of sunitinib, a tyrosine kinase receptor
inhibitor used for the treatment of various tumor types. Importantly, these untoward effects …

Sir: A 49-year-old man presented with dyspnoea, peripheral oedema and coldness for which
he had daily taken a bath during the previous few weeks. He admitted excessive alcohol use …